COMMUNIQUÉS West-GlobeNewswire

-
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024
30/07/2024 -
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 30 - 2024
30/07/2024 -
H1 2024 Results - Focus-27 strategic plan on track with timely execution of the operational roadmap
30/07/2024 -
RESULTATS DU PREMIER SEMESTRE 2024 - Le plan stratégique Focus-27 est en bonne voie avec une exécution dans les délais de la feuille de route opérationnelle
30/07/2024 -
La Croix-Rouge canadienne annonce une aide financière pour les personnes évacuées de Jasper en raison des feux de forêt en Alberta
30/07/2024 -
BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms
30/07/2024 -
Ostomy Care Brand Revel Launches Groundbreaking Deodorizing Lubricant
30/07/2024 -
KabaFusion Selected by GC Biopharma USA, Inc. as a Limited Distribution Partner for Partner of ALYGLO™ for Adults With Primary Humoral Immunodeficiency (PI)
30/07/2024 -
AMN Healthcare Introduces Televate™ Teletherapy Platform for Students K-12
30/07/2024 -
Texicare Selects CirrusMD to Provide Access to On-Demand Virtual Care for Small Employer Groups in Texas
30/07/2024 -
Acentra Health Honored as an AWS Champion for Digital Transformation in the Public Health Sector
30/07/2024 -
Marius Pharmaceuticals Submits KYZATREX® (Testosterone Undecanoate) CIII Capsules for Approval to Health Canada
30/07/2024 -
Sanara MedTech Inc. Announces Second Quarter Earnings Release and Conference Call Dates
30/07/2024 -
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
30/07/2024 -
Arch Biopartners Arranges Non-Brokered Private Placement
29/07/2024 -
Earth Science Tech, Inc., Reports its June 30, 2024, Quarter Results, Recording Over $8.5M in Revenue and $1.07M in Net Profit
29/07/2024 -
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
29/07/2024 -
Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024
29/07/2024 -
Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024
29/07/2024
Pages